CEO Nick Leschly shifting to chair as 2seventy bio restructures
Plus: CFO Galá promoted at Jazz, and updates from Geron, Mirum, ReNAgade, Inmagene and more
2seventy bio Inc. (NASDAQ:TSVT) is looking for a new CEO to succeed Nick Leschly, who is stepping down as part of a restructuring that the company hopes will save at least $130 million in 2024-25 and extend its runway into 2026. 2seventy also named CFO Chip Baird as COO, and said it expected to appoint Leschly as chair once a new CEO had been found. Changes to the company’s R&D strategy include the expansion of its collaboration with JW Therapeutics Co. Ltd. (HKEX:2126) to include new solid tumor and autoimmune programs and limiting investment in its bbT369 and SC-DARIC33 programs pending further clinical data readouts. About 40% of the company’s workforce is expected to be cut as part of the restructuring.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) promoted CFO Renée Galá was to president and COO, effective Oct. 1. Galá succeeds Dan Swisher, who is retiring but will continue to serve in a strategic adviser role through March 2024...